Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDELYX, INC. (ARDX) is the issuer in a Rule 144 notice filed for planned sales of its common stock by Michael Raab. The notice covers 44,500 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $179,335.00, based on an issuer share count of 249,187,572 shares. Sales may occur on or before 08/21/2026 on NASDAQ. The filing also identifies 108,840 shares of common stock issuable upon vesting of restricted stock units on 08/19/2026, to be sold solely to cover applicable withholding taxes pursuant to an automatic sell-to-cover feature.
ARDELYX, INC. (ARDX) has a notice under Rule 144 for potential sales of common stock by Laura A. Williams. The notice covers 10,500 shares of common stock, with an aggregate market value of $42,315.00, based on an issuer share count of 249,187,572 shares as of the notice. The shares relate to the 08/19/2026 vesting of 24,041 restricted stock units, characterized as issued for services rendered. The issuer states the sales are pursuant to an automatic sell-to-cover mechanism imposed by the original RSU grant, with shares to be sold solely to cover applicable withholding taxes. In the prior three months, Williams reported multiple sales, including 81,898 shares for $490,487.12 on 06/18/2026.
ARDELYX, INC. (ARDX) officer Joseph James Reilly filed a notice of proposed sale of company common stock under Rule 144. The filing lists a planned sale of 4,700 shares through Morgan Stanley Smith Barney LLC, with an indicated aggregate value of $18,941.00, in connection with restricted stock units (RSUs) vesting on 08/19/2026. The RSUs vest for 10,388 shares, and the filing states the shares are to be sold solely to cover applicable withholding taxes under an automatic sell‑to‑cover provision. It also reports prior sales on 05/21/2026 totaling 3,719 shares at aggregate values of $16,815.70 and $6,493.13.
ARDELYX, INC. (ARDX) is the issuer of common stock covered by a notice of proposed sale under Rule 144 filed for the account of John E. Bishop. The filing states a brokerage arrangement with Morgan Stanley Smith Barney LLC for 25,500 shares of common stock, with an approximate aggregate market value of $102,765.00, and indicates the shares are listed on NASDAQ. The notice also describes that shares issuable upon vesting of restricted stock units on 08/19/2026 are to be sold solely to cover applicable withholding taxes pursuant to an automatic sell-to-cover feature in the original RSU awards. In the prior three months, a separate sale of 2,306 shares of common stock for $14,452.86 is reported.
ARDELYX, INC. (ARDX) received a Rule 144 notice for planned sales of its common stock by officer Brady James Parker. A brokerage account at Morgan Stanley Smith Barney LLC lists 19,700 shares of common stock with an aggregate market value of $79,391.00, relative to 249,187,572 shares outstanding.
The notice also reports that 47,716 shares are to be sold in connection with the 08/19/2026 vesting of restricted stock units as compensation for services rendered, with sales described as being pursuant to an automatic sell-to-cover arrangement to satisfy applicable withholding taxes. During the prior three months, 1,846 shares of common stock were sold for $11,569.81.
ARDELYX, INC. (ARDX) is the issuer for a notice of proposed sale of securities filed for the account of officer Eric Duane Foster under Rule 144. The filing indicates a planned sale of 11,900 shares of common stock through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $47,957.00 as of the notice. The shares relate to the vesting of restricted stock units on 08/19/2026, with the issuer listed as the party from whom the securities were acquired for services rendered. The remarks state that the sale is pursuant to an automatic sell-to-cover feature to cover applicable withholding taxes upon vesting.
The notice also lists sales of ARDELYX common stock by Eric Duane Foster during the prior three months on 05/21/2026 in three transactions of 3,166, 2,427, and 2,405 shares, for consideration of $19,842.91, $15,211.22, and $15,073.34, respectively.
Ardelyx, Inc. reported a leadership change with the resignation of its Chief Commercial Officer, Eric Foster. Foster informed the company of his decision on August 11, 2026, and his resignation is effective August 28, 2026. The company states that he is leaving to pursue a new opportunity with a pre-commercial company and that his resignation is not due to any disagreement with Ardelyx. Ardelyx remains incorporated in Delaware and its common stock, par value $0.0001 per share, continues to trade under the symbol ARDX on The Nasdaq Global Market.
Rubric Capital Management LP and David Rosen reported beneficial ownership of 16,202,700 shares of Ardelyx, Inc. common stock on a passive ownership basis. This represents 6.56% of Ardelyx’s outstanding common stock, based on 247,029,387 shares outstanding as of April 23, 2026.
The reporting persons have shared voting and dispositive power over all 16,202,700 shares and no sole voting or dispositive power. Rubric Capital Master Fund LP, one of the Rubric funds, has the right to receive or direct dividends and sale proceeds for more than 5% of the common stock.
Ardelyx, Inc. has a significant shareholder group led by investment entities affiliated with Millennium. Integrated Core Strategies (US) LLC reports beneficial ownership of 12,030,115 shares of Ardelyx common stock, representing 4.8% of the class, all with shared voting and dispositive power and no sole power. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 14,200,773 shares, or 5.7% of the outstanding common stock, again entirely on a shared basis for both voting and dispositive power and with no sole authority. The filing explains that these securities are held by entities over which Millennium Management LLC and related managers exercise voting control and investment discretion, and it includes language stating that this structure should not, by itself, be construed as an admission of beneficial ownership by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander.
Ardelyx, Inc. reported strong top-line growth but remained unprofitable. For the six months ended June 30, 2026, total revenues were $215,350 (in thousands), up 25% year over year, driven by product sales, net of $211,502 (in thousands). Net loss narrowed to $54,326 (in thousands), or $0.22 per share, versus $60,223 (in thousands), or $0.25 per share, a year earlier.
IBSRELA generated $156,317 (in thousands) and XPHOZAH $55,185 (in thousands) in product sales for the first half, reflecting higher demand and pricing. Gross-to-net adjustments increased, lifting the GTN percentage to 35.0% for the half. Cost of sales fell 57% as AstraZeneca royalty costs ended, while research and development and selling, general and administrative expenses rose on CIC Phase 3 trial spending and commercialization support.
Liquidity remained solid, with $281,830 (in thousands) in cash, cash equivalents and short-term investments and $250,000 (in thousands) of term debt outstanding under a loan facility now maturing July 1, 2030 after an April 2026 amendment. Ardelyx continues to emphasize risks from ongoing losses, heavy reliance on IBSRELA and XPHOZAH, and the inclusion of XPHOZAH in the ESRD PPS, which eliminated Medicare Part D coverage and, according to the company, has had a negative and material impact on XPHOZAH revenue and will result in a materially lower pace of revenue growth.